Short answer: in human trials LGD-4033 (ligandrol, VK5211) was dosed at 0.1 to 2 mg a day. In healthy young men, 1 mg a day for 21 days added 1.21 kg of lean mass and also lowered testosterone, SHBG and HDL cholesterol (Basaria 2013). Users commonly report 5–10 mg a day, and some 20–30 mg; those doses have never been studied.
Below: every dose that has been tested, the half-life, what users report, and why there is no proven “no-PCT” dose.
Ligandrol summary
LGD-4033, also called ligandrol and, in later trials, VK5211, is a nonsteroidal SARM. Its first trial in healthy men was funded by Ligand Pharmaceuticals (Basaria 2013), and the later Phase 2 trial as VK5211 was sponsored by Viking Therapeutics (NCT02578095). It is not approved anywhere we could find, and no Phase 3 trial has been registered.
| Trial | Dose | Who and how long | Main results |
|---|---|---|---|
| Basaria 2013 | 0.1, 0.3 or 1.0 mg/day | 76 healthy men aged 21–50, 21 days | Lean mass +1.21 kg at 1 mg; strength and fat mass not significantly changed; testosterone, SHBG, HDL and triglycerides down with dose; back to baseline by day 56 |
| VK5211 Phase 2 (NCT02578095) | 0.5, 1.0 or 2.0 mg/day | 108 adults 65+ after hip fracture, 12 weeks | Lean mass +4.75%, +7.15% and +9.08% vs placebo; serious adverse events 4/28 on placebo vs 2/29, 3/26 and 5/25 |
| Dose studied | Who took part | Duration | What the study found | Source |
|---|---|---|---|---|
| 0.1, 0.3 or 1.0 mg/day | Healthy men aged 21–50 (n=76) | 21 days (followed 5 more weeks) | Randomized, double-blind, placebo-controlled Lean body mass rose with dose, by 1.21 kg on 1.0 mg. Fat mass, leg-press strength and stair-climbing power did not change significantly vs placebo. Total testosterone, SHBG, HDL and triglycerides fell with dose; FSH and free testosterone fell on 1.0 mg. Hormones returned to baseline by day 56. | PubMed 2013 |
| 0.5, 1.0 or 2.0 mg/day (as VK5211) | Adults aged 65 and over, 3–7 weeks after a hip fracture (n=108) | 12 weeks | Randomized, double-blind, placebo-controlled Phase 2, multicenter Lean mass (whole body minus head, by DXA) rose 4.75%, 7.15% and 9.08% more than placebo on the three doses. Serious adverse events: 4 of 28 on placebo, 2 of 29, 3 of 26 and 5 of 25 on the three doses. | clinicaltrials.gov 2017 |
Sources: the studies linked in the table.
More on the compound in the LGD-4033 fact sheet; compare it with other SARMs in the SARMs database.
Ligandrol half-life
The half-life of LGD-4033 is 24–36 hours in healthy men. It builds up with daily dosing: blood levels on day 21 were nearly three times those on day 1, and exposure rose in proportion to the dose (Basaria 2013). The trial authors say this suits once-daily or even less frequent dosing; timing within the day is covered in when to take LGD-4033.
24–36 hours
half-life in healthy men
day 56
hormones back to baseline after 21 days at up to 1 mg
40 days
a breakdown product was still found after micro-doses
After 21 days at up to 1 mg, hormones were back to baseline by day 56, about five weeks after the last dose. Recovery after longer or higher-dose use has not been studied. Anti-doping tests detect it much longer: a breakdown product was still found more than 40 days after five 50 µg micro-doses (Wagener 2022).
LGD 4033 (Ligandrol) dosage
There is no approved or recommended dose, because LGD-4033 is not an approved medicine. Two kinds of numbers exist:
| Source | Dose | Evidence |
|---|---|---|
| Healthy young men (21 days) | 0.1–1 mg/day | Randomized trial |
| Older adults after hip fracture (12 weeks) | 0.5–2 mg/day | Randomized trial |
| Commonly reported by users | 5–10 mg/day for 6–8 weeks | Anecdotal |
| Higher user doses (e.g. 20–30 mg) | Not studied | Anecdotal |
Every hormonal and lipid change in the 21-day trial grew with the dose, from 0.1 to 1 mg. That is the best available guide to what higher doses are likely to do, but effects above 2 mg a day are not established.
What the study found: Cardaci 2022
- Population
- one documented case: a 25-year-old man
- Dose
- 10 mg LGD-4033 with 15 mg MK-677
- Duration
- 5 weeks
- Result
- Total testosterone down 62%, HDL down 36%, LDL up 40% and ALT up 205%
Women: no trial has reported results for women taking LGD-4033 separately, so doses suggested for women online are not based on data.
Liquids: the dose depends on the concentration on the label; at 10 mg per ml, 1 ml contains 10 mg, so 0.1 ml contains 1 mg. Products are often mislabeled: only 41% of 44 tested SARM products matched the label (Van Wagoner 2017).
Warning
Liver: case reports describe cholestatic liver injury in men using ligandrol products, with bilirubin up to 30 times the upper limit in one case (Barbara 2020). A liver panel before and during use is how this is caught.
No PCT LGD 4033 dosage
No dose of LGD-4033 has been shown to avoid suppression. In the trial, total testosterone and SHBG fell at every dose from 0.1 mg, and free testosterone and FSH also fell at 1 mg a day (Basaria 2013). Levels recovered without treatment after 21 days of use; whether that holds after 8 weeks at 2.5–5 mg, as in the reported stacks below, is not known.
Source: Sarmguide compound database; LGD-4033: The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men (2013).
The stacks below are the ones users describe as “no PCT”. Bloodwork before and after is the only way to know where you stand; the PCT and bloodwork planner lists the markers, and LGD-4033 PCT covers what studies say about recovery.
No PCT body recomposition dosage
Evidence level: anecdotal. These stacks and doses are what users commonly report. They have not been studied, and the doses are several times higher than any trial. This is a description, not a protocol.
Reported: LGD-4033 at 5 mg a day with SR9009 (Stenabolic) at 30 mg a day for 8 weeks. Claims of about 2.5 kg fat lost and 2.5 kg muscle gained are user estimates. SR9009 has never been tested in people, and liver injury has been reported with it (Shams Bin Shaheen 2026); see SR9009 dosage.
No PCT Bulking Dosage
Evidence level: anecdotal. These stacks and doses are what users commonly report. They have not been studied, and the doses are several times higher than any trial. This is a description, not a protocol.
Reported: LGD-4033 at 5 mg a day plus MK-677 at 15 mg a day for 8 weeks, then MK-677 alone for 8 more weeks. MK-677 does not restore testosterone; in one trial it lowered total testosterone vs placebo (Svensson 1999), and the documented LGD-4033 + MK-677 case above shows how far hormones can fall. See the LGD-4033 and MK-677 stack review.
No PCT Cutting Dosage
Evidence level: anecdotal. These stacks and doses are what users commonly report. They have not been studied, and the doses are several times higher than any trial. This is a description, not a protocol.
Reported: LGD-4033 at 2.5 mg a day with SR9009 at 30 mg a day for 8 weeks, or ostarine at 15 mg a day in place of the LGD-4033. Both SARMs lowered testosterone in trials at much lower doses (1 mg LGD-4033; 1–3 mg ostarine, Dalton 2011).

Conclusion
The only tested LGD-4033 doses are 0.1–2 mg a day, and even 1 mg a day lowered testosterone, SHBG and HDL within three weeks. The 5–10 mg (and higher) doses users report have never been studied; the documented effects all grew with dose. If you compare options, the database and RAD-140 vs LGD-4033 show how ligandrol stacks up, and the LGD-4033 before and after page shows what users report.
Frequently asked questions
What is the LGD-4033 dosage used in studies?
0.1 to 2 mg a dayEvidence: Trial
Trials used 0.1, 0.3 or 1.0 mg a day for 21 days in healthy young men, and 0.5, 1.0 or 2.0 mg a day for 12 weeks in older adults after hip fracture. No higher dose has been published.
Is 30 mg of LGD-4033 too much?
Never studied; far above trialsEvidence: Trial
30 mg a day is 15 times the highest dose tested in people (2 mg), and its effects are not established. In the 21-day trial every hormonal and cholesterol change grew with the dose.
What does 5 mg or 10 mg of LGD-4033 do?
Not studiedEvidence: Trial
These are common user doses, not tested ones. They are 5–10 times the 1 mg dose that already lowered testosterone, SHBG and HDL in the trial.
What is the half-life of LGD-4033?
24–36 hoursEvidence: Trial
24–36 hours in healthy men; with daily dosing, levels on day 21 were nearly three times those on day 1.
Can you take LGD-4033 without PCT?
No dose avoids suppressionEvidence: Trial
Total testosterone and SHBG fell at every dose from 0.1 mg a day. After 21 days at up to 1 mg, hormones recovered by day 56 without treatment; longer or higher-dose use was not studied.
How much LGD-4033 should a woman take?
No data-based doseEvidence: Limited
No trial has reported results for women taking LGD-4033 separately, so doses suggested for women online are not based on data.
How long should an LGD-4033 cycle be?
Not establishedEvidence: Trial
Trials lasted 21 days and 12 weeks, and no study compared cycle lengths. Longer periods reported by users are anecdotal.
Sources
- The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men
- ClinicalTrials.gov NCT02578095: Acute Hip Fracture Study in Patients 65 Years or Greater (VK5211), posted results
- Investigations into the elimination profiles and metabolite ratios of micro-dosed selective androgen receptor modulator LGD-4033 for doping control purposes
- LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report
- Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet
- Ligandrol (LGD-4033)-Induced Liver Injury
- Acute Liver Failure in an Adolescent Following Use of the Synthetic REV-ERB Agonist SR9009
- Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677
- The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial
- PubChem: LGD-4033 / Ligandrol (CID 44137686), names and synonyms